Medical News

RSS

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

21 May 2010

AACN and Elsevier/MC Strategies to develop online nursing courses

Elsevier/MC Strategies, a pioneer in providing e-learning solutions to more than 1,300 healthcare organizations, has partnered with the American Association of Critical-Care Nurses (AACN) to develop a series of online nursing courses.

21 May 2010

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.

21 May 2010

Datasource Mobility to illustrate new healthcare product from Panasonic

DataSource Mobility is pleased to announce that it is one of a select group of Toughbook Preferred Partners to sell the Toughbook C1—the newest healthcare specific product from Panasonic®, the world leader in rugged mobile computers.

From PHC Europe B.V. 21 May 2010

Cord Blood America reviews first quarter results

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that its co-founder and CEO, Matthew Schissler, reviewed first quarter results and progress in an interview with analyst Francis Gaskins.

21 May 2010

ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting

ZIOPHARM Oncology, Inc. announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque, lead author of the abstract on the palifosfamide study entitled, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)", will present in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 7th at 2:15 pm in the Vista Room (location S 406).

21 May 2010

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Sorrento Therapeutics, Inc. today announced that it has received an Advanced Technology Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus infections, including methicillin-resistant S. aureus, by disrupting quorum sensing, a bacterial communication process essential to virulence.

21 May 2010

New research seeks customised treatment of cardiovascular diseases

The Centre for Cooperative Research in Biomaterials, CIC biomaGUNE, is involved in the research consortium of cvREMOD, which aims to move forward in the attainment of new diagnosis techniques for prevention and customised treatment of cardiovascular diseases in the upcoming four years.

21 May 2010

UF awarded $1.2M grant to support UF-HHMI Science for Life Program

Imagine a chemistry professor and a neuroscientist working together to test a new drug to fight Alzheimer's disease, or a biomedical engineer working with an orthopedic surgeon to help patients walk again.

21 May 2010

New synthesized genome may lead to advances in health and biotechnology

The successful construction of a synthesized genome could enable new research and development of human therapies, biofuels, and biobased chemicals from renewable resources.

21 May 2010

'Teachable moments' can reduce cancer risk in children of parents with mutations in tumor suppressor genes

Parents found to be carriers of a mutated form of the tumor suppressor genes known as BRCA1 and BRCA2 do not always share these test results with their children, but they may choose to discuss related information important to their own health with them. That is the result of a study conducted by an investigator at The Cancer Institute of New Jersey (CINJ) and colleagues, whose findings suggest that those parents are using the discovery of their mutation status as an opportunity for a "teachable moment" in educating their offspring about cancer risk reduction.

21 May 2010

Routine cessation of clopidogrel in patients before colonoscopy polypectomy not necessary: Researchers

Researchers at the Syracuse Veterans Affairs Medical Center in New York examined postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel and found that the postpolypectomy bleeding rate is significantly higher in patients undergoing polypectomy while taking clopidogrel and concomitant aspirin/nonsteroidal anti-inflammatory drugs, but that the risk is small and the outcome is favorable.

21 May 2010

Top scientists to share latest research on autism at IMFAR 2010

Autism Speaks, the world's largest autism science and advocacy organization, is a major sponsor and scientific participant in the 2010 International Meeting for Autism Research (IMFAR).

21 May 2010

Restoration of post-meal blood vessel expansion may help improve strength and health in elderly people

Why do people become physically weaker as they age? And is there any way to slow, stop, or even reverse this process, breaking the link between increasing age and frailty?

21 May 2010

Rice University researcher receives 2010 Glycerine Innovation Award

Escherichia coli - E. coli for short - is often identified as a bacterium that contributes to foodborne illness. But research led by a Rice University scientist has discovered ways to use a safe, non-pathogenic E. coli to convert glycerine into high value fuels and chemicals.

21 May 2010

Transplant centers should utilize DCD kidneys to minimize patients’ mortality rates

In the United States over 80,000 people are on the kidney transplant waiting list, and thousands die each year waiting for transplants. For most dialysis patients, kidney transplantation increases their chances of survival.

21 May 2010

Research team investigates infants with suspected GERD using combined pH/MII monitoring

Gastroesophageal reflux, defined as passage of gastric contents into the esophagus is a normal process that occurs in healthy infants, children and adults. When GER causes troublesome symptoms and/or complications it is referred to as gastroesophageal reflux disease. During infancy, GER is common and can manifest with specific symptoms as vomiting and non-specific symptoms as irritability and cough. Association of non-specific symptoms with GER is a main problem in the diagnosis of GERD.

21 May 2010

Compatibility between donated kidney's weight and weight of recipient improves success of transplantation

Receiving an organ low in weight in relation to the recipient's body weight increases kidney transplant recipients risk of complications and transplant failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that compatibility between a donated kidney's weight and the weight of the recipient could improve the success of transplantation.

21 May 2010

Pressure treated playground structures are not harmful for children: Study

Pressure treated wooden playground structures do not live up to the bad reputation they have earned as being harmful to children, according to the findings of a new University of Alberta study.

21 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

Medical News

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

AACN and Elsevier/MC Strategies to develop online nursing courses

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Datasource Mobility to illustrate new healthcare product from Panasonic

Cord Blood America reviews first quarter results

ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

New research seeks customised treatment of cardiovascular diseases

UF awarded $1.2M grant to support UF-HHMI Science for Life Program

New synthesized genome may lead to advances in health and biotechnology

'Teachable moments' can reduce cancer risk in children of parents with mutations in tumor suppressor genes

Routine cessation of clopidogrel in patients before colonoscopy polypectomy not necessary: Researchers

Top scientists to share latest research on autism at IMFAR 2010

Restoration of post-meal blood vessel expansion may help improve strength and health in elderly people

Rice University researcher receives 2010 Glycerine Innovation Award

Transplant centers should utilize DCD kidneys to minimize patients’ mortality rates

Research team investigates infants with suspected GERD using combined pH/MII monitoring

Compatibility between donated kidney's weight and weight of recipient improves success of transplantation

Pressure treated playground structures are not harmful for children: Study

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News